← References
Medical Research Journal Article 2017

Half-life extension technologies for haemostatic agents

Mannucci PM

Blood

Summary

Review of recombinant clotting factor technology — laboratory-manufactured alternatives to plasma-derived factors. Important distinction for patients: recombinant factors are not derived from donated blood, offering a non-blood-derived option for hemophilia management and surgical hemostasis.

Key Excerpts

Recombinant clotting factors are produced using genetic engineering technology without the use of human blood or plasma, eliminating the risk of blood-borne pathogen transmission.

Introduction

Access

Related Topics

alternatives clotting-factors